Brain

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant…

5 months ago

Avio Health Launches AI Platform to Turn Disconnected Health Data into Preventive Intelligence

How Avio Health Is Rewiring Medicine for the Age of AI PALO ALTO, Calif. , July 15, 2025 /PRNewswire/ -- Today,…

5 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)…

5 months ago

Real World Data Supports Results of Route 92 Medical’s SUMMIT MAX Clinical Trial

Company also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meetingSAN MATEO, Calif., July 14,…

5 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

5 months ago

Study Finds Link Between Brain Injury and Criminal Behavior

Study shows criminality is associated with damage to a key brain pathway involved in emotional control and judgment  AURORA, Colo.,…

5 months ago

From Lab to Living Room: New Nonprofit Helps Families Deepen Emotional Connection at Home

Science-backed tools help parents and children connect—improving emotional well-being and reducing behavior struggles NEW YORK, July 10, 2025 /PRNewswire/ --…

5 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

Positive Discussion on Path Forward for Registrational ProgramPURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company…

6 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye…

6 months ago

Diagonal Therapeutics Announces Publication of Data Characterizing the Healthcare System Cost and Impact of Hereditary Hemorrhagic Telangiectasia (HHT) in the American Journal of Hematology

WATERTOWN, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering…

6 months ago